Monday, January 21, 2013

Dainippon Sumitomo Pharma establishes a Subsidiary in Singapore

Dainippon Sumitomo Pharma Co., Ltd announces the establishment of a wholly owned subsidiary in Singapore as a base of operations in Southeast Asia. DSP is progressing its global expansion with its global strategic product, antipsychotic lurasidone hydrochloride (generic name) at the core. As a part of this effort, DSP has considered extending commercial operations for lurasidone hydrochloride to countries in Southeast Asia where growth is expected in the mid-to long term.
DSP will first promote business operations such as obtaining approval for and marketing lurasidone hydrochloride in Southeast Asia through partnerships with local companies. Further in the future, using Singapore as a base of operations, DSP will consider successive expansion of its product lineups in Southeast Asia and additionally business expansion into neighboring countries such as Australia.












Enter your email address:


Delivered by FeedBurner